Table 3.
Adverse events
| Treatment group | AEs listed by patient | Incidence, n (%)
|
|||
|---|---|---|---|---|---|
| Any AE | Ocular AE | Treatment-related AEa | Treatment-related ocular AE | ||
| Bimatoprost 0.01% n=67 | Anxiety | 9 (13.4) | 6 (9.0) | 7 (10.4) | 6 (9.0) |
| Superficial punctate keratitis | |||||
| Periorbital pigmentation, sinus drainage | |||||
| Stinging | |||||
| Eye burning, eye pain, foreign body sensation, dizzy | |||||
| Hyperemia, decreased mental clarity | |||||
| Ocular irritation | |||||
| Cardiac ischemiab | |||||
| Exacerbation of depressionb | |||||
| Bimatoprost 0.03% n=62 | Left-sided temporal headache, light flashes OU during periods of darkness | 8 (12.9) | 7 (11.3) | 2 (3.2) | 2 (3.2) |
| Allergic conjunctivitis | |||||
| Redness | |||||
| Subconjunctival hemorrhage | |||||
| Branch retinal vein occlusion | |||||
| Itching eyelid OU | |||||
| Bronchitis | |||||
| Uncontrolled IOP | |||||
Notes:
a
Determined by the investigator to have a possible, probable, or definite relationship to study treatment
b
serious AE (unrelated to treatment).
Abbreviations: AE, adverse event; IOP, intraocular pressure; OU, both eyes.